Stockscreener 앱 받기
153.83
1.24%
1.89
시간 외 거래:
153.83
전일 마감가:
$151.94
열려 있는:
$152.56
하루 거래량:
1.39M
Relative Volume:
0.49
시가총액:
$42.39B
수익:
$21.37B
순이익/손실:
$1.41B
주가수익비율:
39.01
EPS:
3.9437
순현금흐름:
$3.07B
1주 성능:
-1.10%
1개월 성능:
+5.19%
6개월 성능:
-23.67%
1년 성능:
-12.58%
1일 변동 폭
$152.00
$154.93
1주일 범위
$148.23
$159.49
52주 변동 폭
$140.11
$213.08
벡톤 디킨슨 Stock (BDX) Company Profile
명칭
Becton Dickinson Co
전화
(201) 847-6800
주소
ONE BECTON DR, FRANKLIN LAKES
Compare BDX vs ISRG, MDLN, ALC, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BDX
Becton Dickinson Co
|
153.83 | 41.87B | 21.37B | 1.41B | 3.07B | 3.9437 |
ISRG
Intuitive Surgical Inc
|
407.12 | 144.07B | 10.58B | 3.00B | 2.83B | 8.2437 |
MDLN
Medline Inc
|
40.58 | 34.70B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
69.00 | 33.07B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
198.50 | 29.57B | 5.54B | 1.52B | 1.74B | 10.37 |
벡톤 디킨슨 Stock (BDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 재개 | Goldman | Neutral |
| 2026-02-10 | 재개 | Barclays | Overweight |
| 2026-02-03 | 재개 | Citigroup | Buy |
| 2025-09-25 | 개시 | RBC Capital Mkts | Sector Perform |
| 2025-05-22 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-05-02 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-05-02 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-05-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2025-05-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-05-01 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-05-01 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-10-01 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-24 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Overweight |
| 2023-05-05 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-04-12 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2023-01-03 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-12-12 | 업그레이드 | Citigroup | Sell → Neutral |
| 2022-07-11 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2022-06-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-03-18 | 재개 | Raymond James | Mkt Perform |
| 2022-03-02 | 재개 | BofA Securities | Neutral |
| 2021-12-08 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-08-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-05-25 | 개시 | Barclays | Equal Weight |
| 2020-12-15 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-12-15 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-07-09 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-06-01 | 재개 | Goldman | Buy |
| 2020-03-05 | 개시 | Citigroup | Neutral |
| 2020-02-07 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2020-02-07 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2020-02-07 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2020-02-06 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2020-01-08 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2019-05-13 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2018-12-07 | 개시 | Deutsche Bank | Buy |
| 2018-10-16 | 개시 | Barclays | Equal Weight |
| 2018-06-21 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-04-10 | 업그레이드 | Citigroup | Neutral → Buy |
| 2018-01-19 | 재개 | BofA/Merrill | Buy |
| 2018-01-05 | 업그레이드 | Citigroup | Sell → Neutral |
| 2018-01-05 | 개시 | KeyBanc Capital Mkts | Overweight |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2017-12-29 | 재확인 | Deutsche Bank | Buy |
모두보기
벡톤 디킨슨 주식(BDX)의 최신 뉴스
Becton Dickinson & Co. stock outperforms competitors on strong trading day - MarketWatch
XS283900436 Bond Profile — Key Metrics - TradingView
BD Korea expands BD Aptra portfolio with launch of single-use digital flexible cystoscope in Korea - koreabiomed.com
Becton, Dickinson and Company stock: Is BDX underperforming the healthcare sector? - MSN
Evercore Maintains Becton Dickinson & Co(BDX.US) With Buy Rating, Maintains Target Price $180 - 富途牛牛
Becton Dickinson & Co highlights its medical technology footprint as a global healthcare supplier - Ad Hoc News
A Look at Becton Dickinson & Co (BDX) After 3.7% Decline -- GF V - GuruFocus
Becton Dickinson & Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Becton Dickinson (BDX) Following Its Veritor Shift And Index Changes Looks Undervalued - simplywall.st
Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom - The Motley Fool
Becton, Dickinson and (NYSE:BDX) Releases FY23 Earnings Guidance - 富途牛牛
Becton Dickinson and Co steadies operations as healthcare demand evolves - ad-hoc-news.de
Becton Dickinson & Co. stock outperforms competitors despite losses on the day - MarketWatch
Form 4 Becton Dickinson and Co For: 6 July By Investing.com - Investing.com Canada
Evercore ISI Adjusts Price Target on Becton, Dickinson and Company to $180 From $190 - Moomoo
Becton, Dickinson and Company (BDX) Stock Analysis: Evaluating Growth Potential and Analyst Ratings - DirectorsTalk Interviews
Does Vizient’s CentroVena One Deal and Index Shuffle Change The Bull Case For Becton Dickinson (BDX)? - simplywall.st
Becton Dickinson stock gains after company lifts earnings outlook By Investing.com - Investing.com Nigeria
Becton Dickinson & Co (BDX) Stock Forum and Discussion - Moomoo
Becton Dickinson stock holds its setup. Focus shifts to business fundamentals. - AD HOC NEWS
Is It Too Late to Buy Becton Dickinson & Co (BDX) After 3.4% Ral - GuruFocus
Becton Dickinson holds steady as investors await a fresh catalyst - AD HOC NEWS
Becton, Dickinson and Company: Now Is A Great Time To Buy (NYSE:BDX) - Seeking Alpha
Becton Dickinson & Co. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
BD (BDX) Receives Vizient Innovative Technology Contract for CentroVena One Insertion System - Insider Monkey
List of 36 Acquisitions by Becton Dickinson (Jul 2026) - Tracxn
Becton Dickinson (NYSE:BDX) Advances in NYSE Composite After Vizient Deal - Kalkine Media
Becton Dickinson (BDX) Wins Vizient Contract As Fair Value Stays In Focus - simplywall.st
Becton Dickinson & Co. stock underperforms Tuesday when compared to competitors - MarketWatch
Becton Dickinson updates fiscal 2026 outlook, shares steady after cautious guidance - AD HOC NEWS
Form 4 Becton Dickinson and Co For: 26 June By Investing.com - Investing.com India
Insider Sell: Michael Feld Sells Shares of Becton Dickinson & Co (BDX) - GuruFocus
Michael Feld sells $11,460 of Becton Dickinson stock - Investing.com
Becton Dickinson & Co (BDX) Stock Up 3.0% and Still Undervalued -- GF Score: 76/100 - GuruFocus
Becton Dickinson EVP sells $160,226 in BDX shares By Investing.com - Investing.com South Africa
Becton Dickinson EVP sells $160,226 in BDX shares - Investing.com UK
AQR Trend Total Return Fund's Becton Dickinson & Co(BDX) Holding History - GuruFocus
Form 4 Becton Dickinson and Co For: 25 June By Investing.com - Investing.com Australia
Insider Sell: Michael Garrison Sells 1,100 Shares of Becton Dick - GuruFocus
Becton Dickinson and Co (BDX) Valuation: PE, PB & Fair Value Analysis - TradingKey
BD’s central line system gets Vizient’s innovation seal - Stock Titan
Becton Dickinson (BDX) Issues Voluntary Recall for Select Skin Preparation Products - Insider Monkey
벡톤 디킨슨 (BDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.12%
1.75%
자본화:
|
볼륨(24시간):